J. Karp

发表

A phase Ib study of vosaroxin, an anticancer quinolone derivative, in patients with relapsed or refractory acute leukemia

F. Ravandi, J. Lancet, A. List, 2011, Leukemia.

with cytoxan and adriamycin based on induced tumor proliferation Timed sequential chemotherapy of cytoxan-refractory multiple myeloma

P. Burke, J. Karp, R. Humphrey, 2011 .

stimulator and a short-lived inhibitor Relationship of the hematopoietic cycle to the combined activities of a

P. Burke, J. Karp, 2011 .

Humoral factors in aplastic anemia: relationship of liver dysfunction to lack of serum stimulation of bone marrow growth in vitro.

P. Burke, J. Karp, L. Schacter, 1978, Blood.

coincide with induced tumor proliferation A rationale for sequential high-dose chemotherapy of leukemia timed to

P. Burke, J. Karp, W. Vaughan, 2011 .

The correlation of maximal drug dose, tumor recruitment, and sequence timing with therapeutic advantage: schedule-dependent toxicity of cytosine arabinoside.

P. Burke, W. Vaughan, P. Saylor, 1982, Medical and pediatric oncology.

BP1, a new homeobox gene, is frequently expressed in acute leukemias

F. Behm, S. Raimondi, B. Smith, 2000, Leukemia.

Analysis of factors related to bone marrow graft rejection in aplastic anemia: usefulness of measures of broad alloimmunity as predictors.

E. Mellits, C. Kallman, P. Burke, 1981, Transplantation proceedings.

MDR modulation in acute myelogenous leukemia: is it dead?

J. Karp, 2001, Leukemia.

Topoisomerase II levels and drug sensitivity in adult acute myelogenous leukemia.

L. Zwelling, J. Karp, S. Kaufmann, 1994, Blood.

Two-cycle timed-sequential chemotherapy for adult acute nonlymphocytic leukemia.

J. Karp, P. Burke, P. Burke, 1984, Blood.